Compare STWD & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STWD | GKOS |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.0B |
| IPO Year | 2009 | 2015 |
| Metric | STWD | GKOS |
|---|---|---|
| Price | $18.11 | $121.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $20.13 | ★ $133.07 |
| AVG Volume (30 Days) | ★ 2.9M | 634.6K |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | ★ 10.58% | N/A |
| EPS Growth | ★ 4.55 | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $1,844,289,000.00 | $507,442,000.00 |
| Revenue This Year | $283.44 | $23.30 |
| Revenue Next Year | $17.66 | $27.43 |
| P/E Ratio | $15.78 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $16.90 | $73.16 |
| 52 Week High | $20.99 | $130.23 |
| Indicator | STWD | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 60.90 | 63.45 |
| Support Level | $17.64 | $81.54 |
| Resistance Level | $18.62 | $123.09 |
| Average True Range (ATR) | 0.25 | 4.36 |
| MACD | 0.12 | 1.34 |
| Stochastic Oscillator | 91.92 | 91.89 |
Starwood Property Trust Inc is a real estate investment trust principally engaged in originating, acquiring, and managing commercial mortgage loans, commercial mortgage-backed securities, and other real estate investments in the U.S., Australia, and Europe. The company has four reportable business segments: Commercial and Residential Lending, Infrastructure Lending, Property, and Investing and Servicing. The majority of its revenue is generated from the Commercial and Residential Lending segment, which engages mainly in originating, acquiring, financing, and managing commercial first mortgages, non-agency residential mortgages (residential loans), commercial mortgage-backed securities (CMBS), residential mortgage-backed securities (RMBS), and other real estate and related debt investments.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.